Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study

Next Previous
X
Search
Trial Profile

A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Limosilactobacillus reuteri (Primary) ; Limosilactobacillus reuteri (Primary)
  • Indications Acute enterocolitis; Necrotising enterocolitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Connection
  • Sponsors Infant Bacterial Therapeutics

    • Most Recent Events

    • 31 Jul 2024 This study has been completed in Hungary, according to European Clinical Trial Database records.
    • 20 Jul 2024 This trial has been completed in Poland (End Date: 07 Jul 2024), according to European Clinical Trials Database record.
    • 11 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top